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Advanced breast cancer is encountered in around 5-10% of patients with primary breast 3 cancers [1] , and another 10% of the patients develop distant recurrence within 5 years after 4 primary disease and treatment [2, 3] . Once breast cancer has metastasized to distant locations, 5 it is generally considered amenable to palliative rather than curative care. Therefore, the goals 6 of treatment at this later stage are focused on delaying the progression of the metastatic 7 disease, relief of cancer-related symptoms and maintaining quality of life [1] .
8
The majority of patients with metastatic breast cancer (MBC) are subjected to targeted Withholding certain a priori ineffective treatments in some patients while immediately 17 switching to other last resort treatments in others can have a positive impact on their survival.
18
TTs have been tested in randomized controlled trials (RCTs) to assess clinical effectiveness 19 in terms of time to disease progression and overall survival [6] . Most of the investigated 20 treatments suggest that TTs could prolong life of MBC patients [7] . However, the extent to 21 which TTs could increase the survival of MBC patients is yet unclear.
22
Previous systematic reviews and meta-analyses have demonstrated that the addition of TT to 23 chemo-and endocrine therapies significantly improved the overall survival (OS) and the 24 progression-free survival (PFS) of HER2-positive and/or HR+ MBC patients [6, 7] . Others 25 reported increased efficacy of trastuzumab in combination with chemotherapy on the median 26 OS [8] and improved OS of these patients when treated with lapatinib [9] . Although these 27 previous reviews clearly demonstrate that TTs improved survival, they did not estimate the 28 absolute effects in terms of duration of time (i.e. months) added to the life of these patients.
29
Since this information is crucial for future cost-effectiveness studies, the aim of this analysis Figure 2 and Figure 3 ). HRs were defined as the risk of recurrence or further spread 7 of the metastatic disease. PFS was defined as the time of randomization until the time of 8 disease progression or death from any cause. OS was defined as the time from randomization 9 until the time of death from any cause. 
Statistical analysis

13
The HRs outcomes were pooled into a forest plot in Review Manager (RevMan) [11] 
Assessment of risk of bias
27
The Jadad scale [13] was used to assess the quality of the selected RCTs. The mean and the 28 median, and the range of the Jadad score was reported for all studies. 
Type of targeted therapy
12
The most commonly investigated TTs in the selected RCTs including large groups of patient 13 population were trastuzumab, bevacizumab and lapatinib, while trastuzumab emtansine, 14 pertuzumab, everolimus and palbociclib were less tested and the number of patients included 15 was smaller (Table 1) . Figure 2 ). In the same subgroup 4 palbociclib demonstrated the highest increase in median PFS, followed by bevacizumab and 5 everolimus ( Table 1, Table 2 ).
6
The heterogeneity of all studies was 84%, Chi 2 =250.59 and p<0.00001, indicating substantial 7 diversity among studies. Overall survival -hazard ratios, median and range
11
The pooled hazard ratio was 0. Table 2 ).
26
The analysis for the subgroup of patients with HER2-negative and HR-positive disease 27 revealed that the use of TTs added 3.6 months [0.6-not estimated] to the median OS of these 28 patients (HRs 0.91, 95% CI 0.84-0.99). First-line TTs showed longer median OS as 29 compared to second-line and beyond TTs, but did not add to the survival of these patients,
30
( Table 1, Table 2 , Figure 3 ). In the same subgroup bevacizumab demonstrated the highest 31 increase in median OS. Lapatinib and palbociclib showed improved median OS, while 32 everolimus did not reach projected OS (Table 1, Table 2 ).
33
The heterogeneity of all studies was 59%, Chi 2 =64.06 and p<0.0001, indicating moderate to 1 substantial diversity among studies. The mean Jadad score of the RCTs used in this review was 3.0 (median 3, range 1 -5). Having in mind the incidence of breast cancer and the fact that MBC is considered incurable
17
[1], even a small increase in PFS and OS could be beneficial for patients with distant relapse. included in these reviews were also included in our analysis. For the RCTs in these reviews 8 Jadad scores were not available for comparison [54, 55] .
9
Another recently published systematic review of Mendes et al [7] concluded that HER2-10 directed therapies had beneficial impact on OS of patients with HER2-positive MBC. 
